Production and Characterization of Protective Human Antibodies against Shiga Toxin 1
AUTOR(ES)
Mukherjee, Jean
FONTE
American Society for Microbiology
RESUMO
Hemolytic-uremic syndrome (HUS) is a serious complication which is predominantly associated in children with infection by Shiga toxin-producing Escherichia coli (STEC). By using HuMAb-Mouse (Medarex) animals, human monoclonal antibodies (Hu-MAbs) were developed against Shiga toxin 1 (Stx1) for passive immunotherapy of HUS. Ten stable hybridomas comprised of fully human heavy- and light-chain immunoglobulin elements and secreting Stx1-specific Hu-MAbs (seven immunoglobulin M(κ) [IgM(κ)] elements [one specific for the A subunit and six specific for the B subunit] and three IgG1(κ) elements specific for subunit B) were isolated. Two IgM(κ) Hu-MAbs (2D9 and 15G9) and three IgG1(κ) Hu-MAbs (5A4, 10F4, and 15G2), all specific for subunit B, demonstrated marked neutralization of Stx1 in vitro and significant prolongation of survival in a murine model of Stx1 toxicosis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=128343Documentos Relacionados
- Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli.
- Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies.
- Isolation and characterization of monoclonal antibodies to Shiga toxin.
- Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin.
- Production and characterization of antibodies against HT-2 toxin and T-2 tetraol tetraacetate.
